# Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective

> **NCT01873248** · EARLY_PHASE1 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 100 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 68Ga-DOTATATE

## Key facts

- **NCT ID:** NCT01873248
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-26
- **Primary completion:** 2017-06-16
- **Final completion:** 2017-06-16
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01873248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01873248, "Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01873248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*